Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ALK/ROS1 inhibitor XZP-3621

An orally bioavailable inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, ALK/ROS1 inhibitor XZP-3621 targets, binds to and inhibits the activity of ALK and ROS1, which leads to the disruption of ALK- and ROS1-mediated signaling and the inhibition of cell growth in ALK- and ROS1-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types. XZP-3621 may be able to inhibit ALK resistance mutations associated with other ALK inhibitors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ALK/ROS1 dual inhibitor XZP-3621
Code name:XZP 3621
XZP-3621
XZP3621
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search